Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company that describes itself as a leading provider of autoimmune diagnostics and autoimmune testing solutions. Based in San Diego County, California, Exagen focuses on chronic and debilitating autoimmune conditions, particularly autoimmune rheumatic diseases. Its news flow reflects both its operational performance and its scientific and clinical activities in this specialized area.
Company news frequently covers financial results and operational updates, including quarterly earnings releases, preliminary annual results, and related guidance. These updates often discuss revenue trends, test volume for the AVISE CTD panel, average selling price metrics, and cash and cash equivalents, giving investors insight into Exagen’s commercial progress as an autoimmune diagnostics provider.
Exagen’s news also highlights developments in its testing portfolio and research programs. The company reports on enhancements to AVISE CTD, such as the commercial launch of seronegative rheumatoid arthritis markers for anti-PAD4, and on scientific milestones like the acceptance of multiple abstracts at the American College of Rheumatology’s annual meeting. These abstracts address topics including urinary biomarker panels for lupus nephritis, kidney-specific biomarker panels, T cell biomarkers, and multianalyte lupus risk scores.
Additional announcements include participation in healthcare and diagnostics investor conferences and leadership appointments, such as the addition of a Chief Scientific Officer and new board members with experience in life sciences and medical technology. Together, these news items give a view into Exagen’s financial performance, scientific focus, and corporate development. Investors and observers can use the XGN news page to follow how the company reports on its autoimmune testing business, research activities, and strategic initiatives over time.
Exagen Inc. (Nasdaq: XGN) will release its financial results for Q1 2022 on May 11, 2022, after market close. The call, hosted by CEO Ron Rocca and CFO Kamal Adawi, will begin at 4:30 PM ET. Interested parties can join via phone or webcast. Exagen focuses on autoimmune testing solutions, aiming to improve patient care through its AVISE® testing products, particularly for conditions like rheumatoid arthritis and lupus. For further details, visit their investor relations website.
Exagen Inc. (Nasdaq: XGN) will participate in the Investor Summit Group’s Q2 Conference in New York City on May 3-4, 2022. The company's President and CEO, Ron Rocca, along with CFO Kamal Adawi, will present on May 4 at 2:00 PM ET. Interested parties can access the webcast on Exagen’s website. Exagen focuses on autoimmune testing solutions to improve patient care through enhanced diagnosis and therapy optimization. The company is known for its AVISE® testing products and proprietary technology aimed at aiding rheumatologists in managing autoimmune diseases.
Exagen Inc. (Nasdaq: XGN) announced a partnership with Evolutions Healthcare Systems, making its AVISE® Lupus and AVISE® CTD tests available as in-network benefits. This agreement enhances care for members needing autoimmune diagnostic testing. Ron Rocca, Exagen’s President and CEO, emphasized the importance of this collaboration in facilitating timely and accurate diagnoses for complex autoimmune diseases. Exagen continues to develop innovative testing solutions aimed at improving patient outcomes in chronic autoimmune conditions.
Exagen Inc. (Nasdaq: XGN) announced its AVISE® tests will soon cover over 90 million lives as an in-network benefit starting June 1, 2022, through a partnership with Centene Corporation and WellCare Health Plans. This coverage will provide vital support to more than 22.7 million members, enhancing care for autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE). Exagen aims to improve diagnostic accuracy and patient outcomes through its innovative testing solutions during the ongoing challenges faced in autoimmune disease management.
Exagen Inc. (XGN) reported record financial results for 2021, with total revenue at $48.3 million, up from $42 million in 2020. The testing revenue reached $47.1 million, marking a 27.8% increase year-over-year. During Q4 2021, revenue was $12.7 million, driven by record testing volumes. Despite these gains, Exagen faced a net loss of $26.9 million for the year. Noteworthy achievements included a retention rate of approximately 99% among providers and the acquisition of exclusive technology for the AVISE® RADR platform. The company expects 2022 revenue between $51 million and $53 million.
Exagen Inc. (Nasdaq: XGN) has formed a new Scientific Advisory Board (SAB) comprised of seven distinguished doctors and rheumatology experts, enhancing its capabilities in autoimmune testing solutions. This esteemed group includes industry leaders such as Stanley Cohen, MD, and Andrew Concoff, MD, among others. The SAB is expected to provide valuable insights that will contribute to the growth and development of Exagen's AVISE® RADR platform. CEO Ron Rocca expressed excitement over the board's potential to guide the company in advancing its goals.
Exagen Inc. (Nasdaq: XGN) announced its participation in the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum on March 22-23, 2022. Ron Rocca, President and CEO, and Kamal Adawi, CFO, will engage in a virtual fireside chat on March 23 at 3:45 PM ET. Interested parties can access the live webcast through Exagen’s website. Exagen focuses on autoimmune testing solutions, aiming to improve care for autoimmune disease patients with its AVISE® brand testing products.
Exagen Inc. (Nasdaq: XGN) will announce its financial results for the year and fourth quarter ended December 31, 2021, on March 22, 2022, after market close. The earnings call will be hosted by key executives, including CEO Ron Rocca, CFO Kamal Adawi, and COO Mark Hazeltine, at 4:30 PM ET. Investors can access the call via phone or webcast, with a replay available until March 29, 2022. Exagen focuses on providing innovative autoimmune testing solutions aimed at improving patient care for diseases like rheumatoid arthritis and lupus.
Exagen Inc. (Nasdaq: XGN) has announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15-17, 2022. CEO Ron Rocca and CFO Kamal Adawi will engage in a virtual fireside chat on February 16 at 2:00 PM ET, accessible to conference attendees. Additionally, one-on-one meetings with investors can be scheduled through BTIG. Exagen specializes in autoimmune testing solutions, aiming to improve care for chronic autoimmune diseases with its AVISE® brand products.
Exagen Inc. (Nasdaq: XGN) has entered a research collaboration and exclusive licensing agreement with Queen Mary University of London to enhance precision medicine approaches for rheumatoid arthritis (RA). This partnership aims to develop patent-pending assays that utilize RNA expression signatures to improve therapeutic selection for RA patients. With approximately two million individuals affected by RA in the U.S., the collaboration seeks to address significant unmet needs in treatment variability. Exagen will market the resulting diagnostics under the AVISE® RADR brand.